Drug Trial Radar · NCT07947043
Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Dec 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jiangsu Dekang Biotechnology Co., Ltd
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single - center, single - arm, open - label, single - dose, dose - escalation exploratory study. The main purpose is to evaluate the safety and tolerability of autologous tumor - infiltrating lymphocyte injection in the treatment of recurrent or metastatic lung cancer or cervical cancer. Meanwhile, it will also preliminarily explore the effectiveness, PK characteristics, PD characteristics and changes in immune - related parameters of autologous tumor - infiltrating lymphocyte injection in subjects with recurrent or metastatic lung cancer or cervical cancer.
Conditions
- Recurrent or Metastatic Lung Cancer or Cervical Cancer
Interventions
Autologous Tumor-Infiltrating Lymphocyte InjectionBiological
DK008
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: Up to 12 months after first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.